ADVA
19.3.2020 09:03:05 CET | Business Wire | Press release
ADVA (FSE: ADV) and NEC Corporation (NEC; TSE: 6701) today announced that Viettel, a global telecommunications service provider based in Vietnam, has deployed ADVA’s Oscilloquartz timing solution throughout Laos and Myanmar to provide nationwide 4G services and prepare its synchronization network for 5G. The technology enables Viettel to smoothly transition its legacy timing infrastructure, deliver 4G coverage to more mobile subscribers and lay the foundations for next-generation services. Installed and maintained by NEC, the new solution is built on ADVA’s OSA 3230B primary reference cesium clock (PRC) for assured and precise synchronization with or without GNSS. It also features ADVA’s versatile ultra-compact synchronization supply units (SSUs) with high-capacity PTP modules for grandmaster clock functionality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005023/en/
“This deployment enables the end-to-end distribution of assured, precise and highly reliable timing. It utilizes our OSA 3230B PRC for superb accuracy with the smallest size and power footprint, as well as our ultra-scalable SSUs. With this solution, we’ve empowered Viettel to address all its most urgent synchronization needs, helped it protect past investments and opened the door to further expansion,” commented Erik Lindberg, VP, sales, APAC, ADVA. “Our close collaboration with NEC was key to the success of this project. It’s a relationship based on a great deal of trust and a shared passion to push the boundaries of possibility. And that partnership is now delivering valuable results for service providers across East Asia.”
Viettel’s new solution leverages the OSA 3230B PRC, a high-performance cesium time source that offers superior accuracy and stability together with operational simplicity and unrivalled flexibility. With its space-saving and environmentally hardened design, it fits seamlessly into a wide range of locations. Also key to the deployment were ADVA’s highly flexible Oscilloquartz SSUs, which enable Viettel to maintain its legacy synchronization networks and evolve ultra-precise, highly reliable timing to meet the requirements of time-sensitive applications and 5G connectivity. All elements of the new timing solution are overseen from Viettel’s headquarters in Vietnam using ADVA’s Ensemble Controller with Sync Director . With its highly intuitive GUI, this advanced management platform guarantees flexibility, cost-effective operations and complete centralized control.
“We’re extremely pleased to be working with our global partner, ADVA, and helping Viettel to achieve its ambitions of taking its timing infrastructure in Laos and Myanmar to the next level. By harnessing the most advanced innovation and our ongoing support, Viettel is ensuring unprecedented levels of precision and reliability as it tackles demand for low-latency services from its mobile customers,” said Mayuko Tatewaki, general manager, service provider division, NEC Corporation. “At NEC, we know the value of synchronization with strict precision. It’s one of the key components when designing 5G-ready networks. Now Viettel has a future-proof timing solution controlled by a single management system and is able to deliver phenomenally accurate phase and frequency alignment all the way from the radio base station to the core.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
About NEC Corporation
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency and equality of society. Under the company’s corporate message of “Orchestrating a brighter world,” NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at www.nec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005023/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom